Literature DB >> 30505514

A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors.

Yong Zhang1, Ling Ye1, Huijun Zhang1, Xuehua Chen1, Haiying Ji1, Gang Chen1, Lu Zhang2, Tengfei Zhang2, Meiling Jin1.   

Abstract

Entities:  

Year:  2018        PMID： 30505514      PMCID： PMC6236185          DOI： 10.21037/jtd.2018.09.101

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Authors:  Jean-Charles Soria; Yi-Long Wu; Kazuhiko Nakagawa; Sang-We Kim; Jin-Ji Yang; Myung-Ju Ahn; Jie Wang; James Chih-Hsin Yang; You Lu; Shinji Atagi; Santiago Ponce; Dae Ho Lee; Yunpeng Liu; Kiyotaka Yoh; Jian-Ying Zhou; Xiaojin Shi; Alan Webster; Haiyi Jiang; Tony S K Mok
Journal:  Lancet Oncol       Date:  2015-07-06       Impact factor: 41.316

Review 3.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Authors:  Matthew G Oser; Matthew J Niederst; Lecia V Sequist; Jeffrey A Engelman
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

Review 4.  Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer.

Authors:  Kazuhiko Shien; Hiromasa Yamamoto; Junichi Soh; Shinichiro Miyoshi; Shinichi Toyooka
Journal:  Acta Med Okayama       Date:  2014       Impact factor: 0.892

Review 5.  FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Weishi Yuan; Kun He; Patricia Keegan; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

Review 6.  Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors:  D Ross Camidge; William Pao; Lecia V Sequist
Journal:  Nat Rev Clin Oncol       Date:  2014-07-01       Impact factor: 66.675

7.  Epidermal growth factor receptor mutations in small cell lung cancer.

Authors:  Akiko Tatematsu; Junichi Shimizu; Yoshiko Murakami; Yoshitsugu Horio; Shigeo Nakamura; Toyoaki Hida; Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 8.  Non-small-cell lung cancer.

Authors:  Cesare Gridelli; Antonio Rossi; David P Carbone; Juliana Guarize; Niki Karachaliou; Tony Mok; Francesco Petrella; Lorenzo Spaggiari; Rafael Rosell
Journal:  Nat Rev Dis Primers       Date:  2015-05-21       Impact factor: 52.329

9.  Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Authors:  Peter Ballard; James W T Yates; Zhenfan Yang; Dong-Wan Kim; James Chih-Hsin Yang; Mireille Cantarini; Kathryn Pickup; Angela Jordan; Mike Hickey; Matthew Grist; Matthew Box; Peter Johnström; Katarina Varnäs; Jonas Malmquist; Kenneth S Thress; Pasi A Jänne; Darren Cross
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

10.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

Authors:  J-Y Douillard; G Ostoros; M Cobo; T Ciuleanu; R McCormack; A Webster; T Milenkova
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.